Dianthus Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DNTH research report →
Range $122 – $158
Price Chart
About the company
Dianthus Therapeutics, Inc. , a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
- CEO
- Marino Garcia
- IPO
- 2018
- Employees
- 92
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on DNTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.76B
- P/E
- 2827.67
- Fwd P/E
- 45.73
- PEG
- 22.53
- P/S
- 1757.54
- P/B
- 3.92
- EV/EBITDA
- -119.87
- Div Yield
- 0.00%
- Gross Margin
- 97.20%
- Op Margin
- -8683.89%
- Net Margin
- -1463.83%
- ROE
- -3.87%
- ROIC
- -18.91%
Latest fiscal year · YoY change
- Revenue
- $2.04M-67.3%
- Gross Profit
- $2.04M-67.3%
- Op Income
- $-177,933,000
- Net Income
- $-162,337,000-91.1%
- EPS
- $-4.20-64.7%
- OCF Growth
- -65.1%
- FCF Growth
- -65.1%
- 52W High
- $117.88
- 52W Low
- $35.84
- 50D MA
- $86.81
- 200D MA
- $87.62
- Beta
- 0.08
- RSI (14)
- 48
- Avg Volume
- 848.11K
No earnings-call transcripts are available for DNTH yet.
- Free Float
- 83.1%
- Shares Outstanding
- 56.31M
- Float Shares
- 46.82M
of shares held by institutions
279 13F filers
Buy/sell ratio 0.53. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 8.55M | ▲ 352.87K |
| Blackrock, Inc. | 4.39M | ▲ 265.78K |
| T. Rowe Price Investment Management, Inc. | 3.89M | ▲ 2.60M |
| Wellington Management Group Llp | 3.23M | ▲ 634.10K |
| Fairmount Funds Management LLC | 2.54M | 0 |
| State Street Corp | 2.53M | ▲ 177.02K |
| Price T Rowe Associates Inc | 2.51M | ▲ 1.37M |
| Vanguard Capital Management LLC | 2.43M | ▲ 268.50K |
| Avidity Partners Management LP | 2.10M | 0 |
| Vanguard Group Inc | 2.05M | ▲ 406.25K |
| Octagon Capital Advisors LP | 1.84M | ▼ 105.00K |
| Tcg Crossover Management, LLC | 1.68M | 0 |
Held by 383 ETFs
Biggest fund positions in DNTH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | Savitz Ryan | other | 40,430 |
| Nov 10, 26 | Savitz Ryan | other | 1,260 |
| Nov 11, 26 | Savitz Ryan | other | 1,300 |
| Nov 9, 26 | Savitz Ryan | other | 10,399 |
| Nov 9, 26 | Savitz Ryan | sell | 300 |
| Nov 9, 26 | Savitz Ryan | sell | 700 |
| Nov 9, 26 | Savitz Ryan | sell | 1,736 |
| Nov 12, 26 | Savitz Ryan | other | 16,385 |
| Nov 9, 26 | Savitz Ryan | other | 40,430 |
| Nov 9, 26 | Savitz Ryan | sell | 37,517 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DNTH coverage
Recent articles, reports, and earnings notes.
No research on DNTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DNTH report →Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $9,118,555.02 in Stock
defenseworld.net · Nov 15
Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?
zacks.com · Nov 9
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 4
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
globenewswire.com · Nov 4
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 2
Dianthus Therapeutics to Participate in Five Investor Conferences During November
globenewswire.com · Nov 2
Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma
globenewswire.com · Oct 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.